Metabolic Phenotyping During Stress Hyperglycemia in Cardiac Surgery Patients

NCT03743025 · Terminated

Last updated 2026-05-28

This clinical trial is studying how blood sugar levels change in people with stress hyperglycemia who undergo heart surgery.

Status Terminated Stopped early and will not restart.

Phase Phase 4 Monitors a drug already on the market.

Type Interventional (clinical trial)

Design Randomized, open-label (no blinding) treatment study

Participants 28 people

Who can join Ages 40–80 · all sexes

Timeline Started 2019-03 · est. completion 2023-05

Where 3 sites · United States

What this study is testing ClinicalTrials.gov NCT03743025 ↗

Description as written by the study sponsor.

This study is a prospective randomized study to examine the effects of exposure to dulaglutide on the prevention of stress-hyperglycemia and the metabolic inflammatory response in the perioperative period.

Treatments tested

Dulaglutide Injection also known as Trulicity Drug

Participants randomized at pre-surgery/anesthesia visit and without a history of DM will receive a single injection of Dulaglutide injection: 0.75 mg/0.5 mL solution in a single-dose pen 1 to 3 days prior to surgery
Saline Injection also known as Sodium Chloride Injection Other

Participants randomized at pre-surgery/anesthesia visit and without a history of DM will receive a single injection of Saline injection/0.5 mL pre-drawn solution 1 to 3 days prior to surgery

Main thing measured	Number of Participants With Blood Glucose Levels (BG) > 140 mg/dl During Post Operative Period
Sponsor	Emory University
Conditions studied	Stress Hyperglycemia
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT03743025 ↗